Carisma Therapeutics Inc
sesenbio.comCarisma Therapeutics Inc (NASDAQ: CARM) is a clinical-stage biopharmaceutical company developing engineered macrophage and monocyte cell therapies for cancer and other serious diseases. The company does not generate product revenue, relying instead on collaboration agreements, grants, and equity financing to fund operations, as disclosed in its 10-K filed 2025-03-31. No product revenue, commercial partnerships with disclosed financials, or named competitors are supported by the excerpts provided.
Products & Services
Engineered macrophage and monocyte cell therapies targeting cancer and other serious diseases. Specific pipeline asset names and clinical stage details are not supported by the provided filing excerpts.
Revenue Model
No product revenue as of the 10-K filed 2025-03-31. The company is pre-commercial and funds operations through equity raises, collaboration agreements, and grants.
Customers & Markets
Oncology and serious disease patient populations. No commercial customers disclosed in the provided excerpts.
Geographic Exposure
Headquarters location and geographic operating footprint are not supported by the provided filing excerpts.
Financial Snapshot
Loading...
